Research News
View articles by month and year
1–9 of 9 articles
-
High-Risk Women Often Don’t Take Risk Reducing Medicines Because of Side Effects
A report written for the U.S. Preventive Services Task Force says that many women at high risk of breast cancer don’t take medicines that can lower that risk because of side effects.
-
Aromasin Reduces Risk But Weakens Bones
Research shows that Aromasin is good at lowering breast cancer risk in high-risk postmenopausal women, but weakens bones.
-
Aromasin Helps Reduce Breast Cancer Risk in High-Risk Women
Research shows that the hormonal therapy Aromasin can lower risk in high-risk, postmenopausal women who've never been diagnosed with breast cancer.
-
Tamoxifen Effectively Lowers Breast Cancer Risk in High-Risk Women Younger Than 55
An analysis of four large studies found that tamoxifen effectively reduces breast cancer risk in women younger than 55 at high risk. This benefit outweighed the costs and potential side effects of treatment.
-
Tamoxifen and Evista Both Good Choices to Reduce Risk
Both tamoxifen and Evista lower the risk of invasive and non-invasive breast cancer in women at high risk, and each medicine has benefits and risks.
-
Do Antidepressants Interfere with Tamoxifen? Results Unclear
While the results aren't definitive, one of two new studies suggests that women who take tamoxifen at the same time as the antidepressant medicines Prozac or Paxil may not get the full benefits of tamoxifen.
-
American Society Clinical Oncology Now Recommends Evista or Tamoxifen to Reduce Risk in High-Risk Women
New guidelines from the American Society of Clinical Oncology (ASCO) now recommend both tamoxifen and Evista (chemical name: raloxifene) to reduce breast cancer risk in post-menopausal women at high risk.
-
Drop in Breast Density Key to Tamoxifen Lowering Risk
A new study suggests that tamoxifen is successful at reducing breast cancer risk only in high-risk women whose breast density decreases by 10% or more during the first year or so of treatment.
-
Protective Tamoxifen May Lead to Earlier Diagnosis of Hormone-Receptor-Negative Cancer
Women at high risk who took tamoxifen and developed hormone-receptor-NEGATIVE breast cancer had the cancer diagnosed earlier compared to women who didn't take tamoxifen. (Tamoxifen doesn't reduce the risk of hormone-receptor-negative breast cancer.)
1–9 of 9 articles
